Keep Current with the Latest in Cell Biology Research

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

Allogene Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors.
[Allogene Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

APC Loss Induces Warburg Effect via Increased PKM2 Transcription in Colorectal Cancer

The effects of APC-loss or Wnt ligand on the identified enzymes, PKM2 and LDHA, as well as Warburg effects were investigated. A linkage between activation of Wnt/β-catenin signalling and cancer metabolism was analysed in tumour of Apcmin/+ mice and CRC patients. The roles of PKM2 in cancer metabolism, which depends on Wnt/β-catenin signalling, were assessed in xenograft-tumours.
[British Journal of Cancer]
APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer | British Journal of Cancer. (n.d.). Retrieved October 19, 2020, from https://www.nature.com/articles/s41416-020-01118-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Identification of BCL-XL as Highly Active Survival Factor and Promising Therapeutic Target in Colorectal Cancer

By RNA sequencing analysis of a pan-cancer cohort comprising >1500 patients and subsequent prediction of protein activity, BCL-XL was identified as the only antiapoptotic BCL-2 protein that was overactivated in colorectal cancer.
[Cell Death & Disease]
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer | Cell Death & Disease. (n.d.). Retrieved October 19, 2020, from https://www.nature.com/articles/s41419-020-03092-7# Cite
Full Article
Bookmark

No account yet? Register

0
Share

Automated Microfluidic Platform for Dynamic and Combinatorial Drug Screening of Tumor Organoids

Scientists present an automated, high-throughput, microfluidic 3D organoid culture and analysis system to facilitate preclinical research and personalized therapies. They validated the system by performing individual, combinatorial, and sequential drug screens on human-derived pancreatic tumor organoids.
[Nature Communications]
Schuster, B., Junkin, M., Kashaf, S. S., Romero-Calvo, I., Kirby, K., Matthews, J., Weber, C. R., Rzhetsky, A., White, K. P., & Tay, S. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11(1), 5271. https://doi.org/10.1038/s41467-020-19058-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell-of-Origin

Researchers FACS-purified epithelial cells from human pancreatic ductal adenocarcinoma and normal pancreas and derived their genome-wide transcriptome and DNA methylome landscapes.
[Cancer Discovery]
Espinet, E., Gu, Z., Imbusch, C. D., Giese, N. A., Buscher, M., Safavi, M., Weisenburger, S., Klein, C., Vogel, V., Falcone, M., Insua-Rodriguez, J., Reitberger, M., Thiel, V., Kossi, S. O., Muckenhuber, A., Sarai, K., Lee, A. Y., Backx, E., Zarei, S., … Trumpp, A. (2020). Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-20-1202 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Pancreatic Cancer Action Network Announces Groundbreaking Clinical Trial Platform Transforming Development Of Treatment Options For World’s Toughest Cancer

The Pancreatic Cancer Action Network announced the launch of Precision PromiseSM, the first of its kind adaptive clinical trial platform for pancreatic cancer patients.
[Pancreatic Cancer Action Network]
Press Release
Bookmark

No account yet? Register

0
Share

Tenascin C Promotes Cancer Cell Plasticity in Mesenchymal Glioblastoma

Researchers identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma subtype with high NF-κB signaling activity. Silencing TNC decreased proliferation, migration and suppresses self-renewal of glioma stem cells.
[Oncogene]
Angel, I., Pilo Kerman, O., Rousso-Noori, L., & Friedmann-Morvinski, D. (2020). Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma. Oncogene, 1–15. https://doi.org/10.1038/s41388-020-01506-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Pharmacological Ascorbate Inhibits Pancreatic Cancer Metastases via a Peroxide-Mediated Mechanism

Several in vitro and in vivo mechanisms involved in pancreatic cancer (PDAC) metastases were investigated following treatment with P-AscH. Serum from PDAC patients in clinical trials with P-AscH were tested for the presence and quantity of circulating tumor cell-derived nucleases.
[Scientific Reports]
O’Leary, B. R., Alexander, M. S., Du, J., Moose, D. L., Henry, M. D., & Cullen, J. J. (2020). Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism. Scientific Reports, 10(1), 17649. https://doi.org/10.1038/s41598-020-74806-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Longden Receives NIH New Innovator Award

Thomas Longden, PhD, assistant professor in the Department of Physiology at the University of Maryland School of Medicine, has received the National Institutes of Health (NIH) Director’s New Innovator Award. The award provides $2.3 million to support an “exceptionally creative early career investigator” as part of the High-Risk, High-Reward Research Program of the NIH Common Fund.
[University of Maryland Baltimore]
Press Release
Bookmark

No account yet? Register

0
Share

AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ (upadacitinib) in Atopic Dermatitis

AbbVie announced that it submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.
[AbbVie]
Press Release
Bookmark

No account yet? Register

0
Share

New Treatment Addressing the Pathogenesis of Psoriasis

Investigators review new insights regarding the pathogenesis of psoriasis, as it relates to dendritic cells, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells.
[International Journal of Molecular Sciences]
Tokuyama, M., & Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. International Journal of Molecular Sciences, 21(20), 7488. https://doi.org/10.3390/ijms21207488 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share